Generation Bio (NASDAQ:GBIO) released its quarterly earnings results on Sunday. The company reported ($0.46) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by ($0.01), MarketWatch Earnings reports.
NASDAQ:GBIO opened at $32.04 on Monday. The stock has a 50-day simple moving average of $26.77. Generation Bio has a twelve month low of $17.00 and a twelve month high of $32.77.
Several equities analysts have issued reports on GBIO shares. BidaskClub raised shares of Generation Bio from a “hold” rating to a “buy” rating in a report on Saturday, October 31st. ValuEngine raised shares of Generation Bio from a “hold” rating to a “buy” rating in a report on Monday, October 19th. Finally, Zacks Investment Research raised shares of Generation Bio from a “sell” rating to a “hold” rating in a report on Tuesday, October 13th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $32.33.
Generation Bio Co, a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of eight programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology.
Featured Story: Understanding Analyst Ratings
Receive News & Ratings for Generation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generation Bio and related companies with MarketBeat.com's FREE daily email newsletter.